Talbot Financial LLC Purchases 7,097 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Talbot Financial LLC increased its position in Thermo Fisher Scientific by 40.8%, acquiring an additional 7,097 shares, which brought its total holdings to 24,499 shares valued at approximately $9.93 million.
• Several large investors, including CBIZ Investment Advisory Services LLC and Anderson Financial Strategies LLC, also purchased shares in Thermo Fisher in the last quarter, contributing to institutional ownership of 89.23%.
• Thermo Fisher Scientific reported a quarterly earnings per share of $5.36, exceeding analyst expectations, and has a positive revenue growth of 2.9% compared to the previous year.

Talbot Financial LLC raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 40.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,499 shares of the medical research company's stock after purchasing an additional 7,097 shares during the period. Talbot Financial LLC's holdings in Thermo Fisher Scientific were worth $9,933,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of TMO. CBIZ Investment Advisory Services LLC lifted its holdings in shares of Thermo Fisher Scientific by 137.5% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock worth $28,000 after acquiring an additional 33 shares during the last quarter. Anderson Financial Strategies LLC bought a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth $30,000. Keystone Global Partners LLC bought a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth $31,000. IMA Advisory Services Inc. bought a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth $35,000. Finally, Smallwood Wealth Investment Management LLC bought a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth $37,000. 89.23% of the stock is owned by institutional investors.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer owned 115,174 shares in the company, valued at $57,697,567.04. This represents a 7.99% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock worth $14,182,963 over the last 90 days. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Price Performance

TMO stock opened at $543.88 on Friday. The firm's 50-day moving average price is $482.58 and its two-hundred day moving average price is $447.27. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $610.97. The stock has a market capitalization of $205.37 billion, a price-to-earnings ratio of 31.46, a PEG ratio of 2.95 and a beta of 0.77. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. During the same quarter in the previous year, the company earned $5.37 earnings per share. The company's revenue for the quarter was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific's payout ratio is currently 9.95%.

Analyst Upgrades and Downgrades

Several research firms have weighed in on TMO. Raymond James Financial reissued an "outperform" rating and issued a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Barclays boosted their price target on shares of Thermo Fisher Scientific from $550.00 to $585.00 and gave the stock an "overweight" rating in a research note on Thursday. Evercore ISI lowered their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Wells Fargo & Company lowered their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research note on Thursday, July 24th. Finally, Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the stock an "outperform" rating in a research note on Tuesday, September 2nd. Fifteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $585.37.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.